Cell Theranostics

Cell Theranostics is a biotechnology company based in Centennial, Colorado, that specializes in the development of radiopharmaceutical agents for the diagnosis and treatment of cancer and other diseases. Operating as a subsidiary of Cell>Point, the company utilizes a proprietary ethylenedicysteine (EC) platform to create theranostic pairs, such as the diagnostic Tc-99m-EC-LHRH and its therapeutic counterpart Re-188-EC-LHRH. Its pipeline includes candidates for imaging solid tumors, assessing cardiovascular apoptosis, and detecting infections, with several programs having reached late-stage clinical trials. However, the company and its founders have been the subject of significant legal scrutiny, including a 2021 SEC enforcement action alleging a multi-million dollar fraudulent investment scheme.